Immunosuppression Effects on Airway Mucociliary Clearance: Comparison Between Two Triple Therapies
Carregando...
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2013
Editora
ELSEVIER SCIENCE INC
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
ANNALS OF THORACIC SURGERY, v.96, n.2, p.473-477, 2013
Resumo
Background. Tacrolimus and mycophenolate have now become the most widely used combination for maintenance immunosuppressive regimens after lung transplantation in comparison with cyclosporine and azathioprine. However, limited information is available with respect to their effects on cells, other than those from the immunologic compartment. We hypothesized that different triple therapies could have different effects on airway mucociliary clearance, playing an important role in respiratory infections observed after lung transplantation. Methods. Ninety rats were assigned to three groups (n = 30 each): control = vehicle, therapy 1 = tacrolimus + mycophenolate + prednisone, and therapy 2 = cyclosporine + azathioprine + prednisone. After 7, 15, or 30 days of treatment by gavage, the animals were killed and the following parameters were studied: mucus transportability, ciliary beating frequency, mucociliary transport velocity, and neutral and acid mucus production. Results. There was a significant decrease in ciliary beating frequency, mucociliary transport velocity, and neutral mucus production in all immunosuppressed animals; indeed, both therapies, mainly therapy 1, caused an increase in acid mucus production for as long as 15 days of treatment. Conclusions. Both triple therapies impaired airway mucociliary clearance of rats, but therapy 1 had a more deleterious effect. These data suggest that these undesirable effects can contribute to the high incidence of respiratory infections observed in patients undergoing lung transplantation. (C) 2013 by The Society of Thoracic Surgeons
Palavras-chave
Referências
- Aguilar-Guisado M, 2007, AM J TRANSPLANT, V7, P1989, DOI 10.1111/j.1600-6143.2007.01882.x
- Beaver BV, 2001, J AM VET MED ASSOC, V218, P669
- Braga KA, 2012, TRANSPL P, V44, P2486
- Braga KAD, 2012, CLINICS, V67, P647, DOI 10.6061/clinics/2012(06)16
- Christie JD, 2011, J HEART LUNG TRANSPL, V30, P1104, DOI 10.1016/j.healun.2011.08.004
- DIBENEDETTO G, 1991, J PHYSIOL-LONDON, V439, P103
- DOLOVICH M, 1987, American Review of Respiratory Disease, V135, pA363
- Hayashi T, 2005, EXP PHYSIOL, V90, P535, DOI 10.1113/expphysiol.2004.028746
- Kanoh S, 1999, AM J PHYSIOL-LUNG C, V276, pL891
- KEENAN RJ, 1995, ANN THORAC SURG, V60, P580, DOI 10.1016/0003-4975(95)00407-C
- Korom S, 2009, EUR J CARDIO-THORAC, V35, P1045, DOI 10.1016/j.ejcts.2009.02.035
- Laube BL, 2007, J HEART LUNG TRANSPL, V26, P138, DOI 10.1016/j.healun.2006.11.005
- Nakajima T, 2011, SEMIN IMMUNOPATHOL, V33, P135, DOI 10.1007/s00281-011-0249-9
- Pazetti R, 2008, ANN THORAC SURG, V85, P1925, DOI 10.1016/j.athoracsur.2008.02.084
- Pazetti R, 2007, CLINICS, V62, P345, DOI 10.1590/S1807-59322007000300021
- Pego-Fernandes PM, 2008, J BRAS PNEUMOL, V34, P273, DOI 10.1590/S1806-37132008000500005
- Randell SH, 2006, AM J RESP CELL MOL, V35, P20, DOI 10.1165/rcnb.2006-0082SF
- READ RC, 1991, EUR RESPIR J, V4, P796
- Reichenspurner H, 2005, J HEART LUNG TRANSPL, V24, P119, DOI 10.1016/j.healun.2004.02.022
- Rivero DHRF, 2001, CHEST, V119, P1510, DOI 10.1378/chest.119.5.1510
- Saldiva PH, 1990, J PNEUMOL, V16, P161
- Silva VFPE, 2011, CLINICS, V66, P1451, DOI 10.1590/S1807-59322011000800024
- Speich R, 2001, CLIN INFECT DIS, V33, pS58, DOI 10.1086/320906
- Taylor Jennifer L, 2006, J Intensive Care Med, V21, P327, DOI 10.1177/0885066606292876
- Treede H, 2012, J HEART LUNG TRANSPL, V31, P797, DOI 10.1016/j.healun.2012.03.008
- VEALE D, 1993, THORAX, V48, P629, DOI 10.1136/thx.48.6.629
- Xavier AM, 2007, ACTA CIR BRAS, V22, P465, DOI 10.1590/S0102-86502007000600009
- Zuckermann A, 2003, J THORAC CARDIOV SUR, V125, P891, DOI 10.1067/mtc.2003.71